Premium
Benzothiazole‐Based‐Bioconjugates with Improved Antimicrobial, Anticancer and Antioxidant Potential
Author(s) -
Kumari Bhawana,
Chauhan Kalpana,
Trivedi Jalpa,
Jaiswal Varun,
Kanwar Shamsher S.,
Pokharel Yuba Raj
Publication year - 2018
Publication title -
chemistryselect
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 34
ISSN - 2365-6549
DOI - 10.1002/slct.201801936
Subject(s) - benzothiazole , chemistry , antimicrobial , in vitro , candida albicans , antioxidant , combinatorial chemistry , biochemistry , microbiology and biotechnology , biology , organic chemistry
Abstract Micro‐organism resistance to the drugs has made it necessary to explore novel antibacterial drugs that have significant toxicities. Herein, we report the bioconjugates of N‐acetyl‐D‐glucosamine with benzothiazole derivatives via ester linkage, which display potent effect against pathogenic micro‐organisms (E. coli, S. aureus and C. albicans). These newly synthesized compounds have also been evaluated for anticancer ( Hep‐2 and caco cell lines) and antioxidant activities. The results supported that bioconjugates suppress pathogenic infections (in‐vitro) more effectively in comparison to equivalent dosage of non‐conjugated benzothiazole. Specifically, bioconjugates of Schiff derivative of methoxy‐benzothiazol (compound 8 ) and nitro‐ benzothiazole (compound 9 ) showed MIC value of 1.25 μg/mL against C. albicans. The above proved potent compound 9 , furthermore, revealed significant activity against Hep‐2 and caco cell lines. In conclusion, this study proved that integration of biocomponent enhances the competence in biological application and the results can be explored as a lead for further improvization for commercialization.